The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Eylea was produced by Bayer.
Currently, GMC guidance and European drug licensing laws say that Lucentis (ranibizumab), from Novartis and Roche, and Bayer/Regeneron's Eylea(aflibercept) - that are approved to treat wet AMD - should be ... Eylea because it is around a tenth of the
d Eylea (aflibercept), which both have licences for DMO.
Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).
The drug was the dominant force in wet AMD treatment for some time, although is now facing a challenge from Bayer's Eylea (aflibercept), which was recommended in 2013. ... The update was significant for Novartis as Eylea is recommended as a monthly
Germany's cost-effectiveness watchdog has concluded that Bayer's Eylea provides no additional benefit over Novartis' rival drug Lucentis in patients with a diabetes-related eye disorder. ... The ruling could mean Bayer may struggle to get favourable
[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...